Drug discovery dilemma and Cura quartet collaboration

Area of Science:

• Drug discovery and development
• Translational science
• Biopharmaceutical research

Background:

• Drug discovery involves diverse stakeholders including academia, industry, government, and foundations.
• Effective collaboration is essential for advancing research and improving public health outcomes.
• Current drug development pathways face challenges in translation and clinical attrition.

Purpose of the Study:

• To explore strategies for strengthening inter-institutional collaboration in drug discovery.
• To establish a framework for translating scientific discoveries into viable drug candidates.
• To improve the success rate of proof of concept (PoC) studies and reduce clinical trial attrition.

Main Methods:

• Convened a conference with prominent scientists from academic, industry, government, and disease advocacy sectors.
• Facilitated discussions on new pathways for inter-institutional collaboration.
• Focused on improving the translation of discoveries, PoC studies, and clinical development.

Main Results:

• Identified the critical need for enhanced collaboration across all sectors involved in drug development.
• Highlighted opportunities to streamline the translation of basic science into clinical applications.
• Emphasized the importance of robust PoC studies to de-risk later-stage development.

Conclusions:

• Stronger partnerships between academic, industry, government, and advocacy groups are vital for efficient drug development.
• A collaborative framework can accelerate the delivery of new therapies to patients.
• Addressing challenges in translation and clinical stages requires a unified approach.